Incidence, survival and prevalence of myeloid malignancies in Europe

European Journal of Cancer

Volumn 48, Issue 17, 2012, Pages 3257-3266

  Visser, O ^a   Trama, A ^b   Maynadie M ^c   Stiller, C ^d   Marcos Gragera, R ^e   De Angelis, R ^f   Mallone, S ^f,f   Tereanu, C ^b   Allemani, C ^b,i   Ricardi, U ^h   Schouten, H C ^g   Zielonk, N ^j   Van Eycken, E ^k   Sundseth, H ^l   Hedelin, G ^m   Bouvier, A M ⁿ   Mounier, M ^o   Woronoff, A S ^p   Buemi, A ^q   Tretarre, B ^r   Colonna, M ^s   Bara, S ^t   Ganry, O ^u   Grosclaude, P ^v   Holleczek, B ^w   Geissler, J ^x   Tryggvadottir, L ^y   Deady, S ^z   Bellu F ^aa   Ferretti, S ^ab   Serraino, D ^ac   Vercelli, M ^ad   Vitarelli, S ^ae   Federico, M ^af   Fusco, M ^ag   Michiara, M ^ah   Giacomin, A ^ai   Tumino, R ^aj   Mangone, L ^ak   Falcini, F ^al   Senatore, G ^am   Budroni, M ^an   Piffer, S ^ao   Crocetti, E ^ap   La Rosa, F ^aq   Contiero, P ^ar   Zambon, P ^as   Gatta, G ^b   Gronchi, A ^b   Licitra, L ^b   Ruzza, M ^b   Sowe, S ^b   Capocaccia, R ^f   Tavilla, A ^f   Dei Tos, A P ^at   England, K ^au   Ursin, G ^av   Rachtan, J ^aw   Gozdz, S ^ax   Zwierko, M ^ay   Bielska Lasota, M ^az   Slowinski, J ^ba   Miranda, A ^bb   Safaei Diba, Ch ^bc   Primic Zakelj, M ^bd   Mateos, A ^be   Izarzugaza, I ^bf   Torrella Ramos, A ^bg   Osca Gelis, G ^e   Ardanaz, E ^bh   Galceran, J ^bi   Martinez Garcia, C ^bj   Sanchez Perez, M J ^bj   Melchor, J M ^bj   Adolfsson, J ^bk   Lambe, M ^bl   Mo ller T R ^bm   Ringborg, U ^bn   Jundt, G ^bo   Usel, M ^bp   Ess, S M ^bq   Spitale, A ^br   Konzelmann, I ^bs   Lutz, J M ^bt   Coebergh, J W W ^bu   Otter, R ^a   Siesling, S ^a   van der Zwan, J M ^a   Greenberg, D C ^bv   Wilkinson, J ^bw   Roche, M ^d   Verne, J ^bx   Meechan, D ^by   Lawrence, G ^bz   Coleman, M P ⁱ   Mackay, J ^ca   Gavin, A ^cb   Brewster, D H ^cc   Kunkler, I ^cd   White, C ^ce   more..

^a Department of Cancer Registry and Research   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j Austrian National Cancer Registry   (Austria)

^k Belgian Cancer Registry   (Belgium)

^l European Cancer Patient Coalition   (Belgium)

^m Cancer Registry of Bas Rhin   (France)

ⁿ ote d'Or Digestive Cancer Registry   (France)

^o Côte d'Or Haematoloical Malignancies Registry   (France)

^p Doubs Cancer Registry   (France)

^q Haut Rhin Cancer Registry   (France)

^r Herault Cancer Registry   (France)

^s Isere's Cancer Registry   (France)

^t Manche Cancer Registry   (France)

^u Somme Cancer Registry   (France)

^v Tarn Cancer Registry   (France)

^w Saarland Cancer Registry   (Germany)

^x CML Advocates Network   (Germany)

^y ICELANDIC CANCER REGISTRY   (Iceland)

^z National Cancer Registry of Ireland   (Ireland)

^aa Alto Adige Cancer Registry   (Italy)

^ab Ferrara Cancer Registry   (Italy)

^ac Friuli Venezia Giulia Cancer Registry   (Italy)

^ad UNIVERSITY OF GENOA   (Italy)

^ae Macerata Province Cancer Registry   (Italy)

^af MODENA CANCER REGISTRY   (Italy)

^ag Napoli Cancer Registry   (Italy)

^ah PARMA CANCER REGISTRY   (Italy)

^ai Piedmont Cancer Registry   (Italy)

^aj CIVILE M P AREZZO HOSPITAL   (Italy)

^ak S MARIA NUOVA HOSPITAL   (Italy)

^al Romagna Cancer Registry   (Italy)

^am Salerno Cancer Registry   (Italy)

^an Sassari Cancer Registry   (Italy)

^ao Osservatorio Epidemiologico   (Italy)

^ap Tuscan Cancer Registry   (Italy)

^aq Umbria Cancer Registry   (Italy)

^ar Varese Cancer Registry   (Italy)

^as Veneto Cancer Registry   (Italy)

^at Local Health Unit No 9 Region of Veneto   (Italy)

^au Malta National Cancer Registry   (Malta)

^av CANCER REGISTRY OF NORWAY   (Norway)

^aw Cracow Cancer Registry   (Poland)

^ax Cancer Registry of Kielce   (Poland)

^ay INSTITUTE OF ONCOLOGY   (Poland)

^az NATIONAL MEDICINES INSTITUTE   (Poland)

^ba MEDICAL UNIVERSITY OF SILESIA   (Poland)

^bb Southern Portugal Cancer Registry   (Portugal)

^bc National Cancer Registry of   (Slovakia)

^bd INSTITUTE OF ONCOLOGY   (Slovenia)

^be Albacete Cancer Registry   (Spain)

^bf Departamento de Sanidad Gobierno Vasco   (Spain)

^bg Castillon Cancer Registry   (Spain)

^bh Navarra Cancer Registry   (Spain)

^bi Tarragona Cancer Registry   (Spain)

^bj ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^bk Regional Cancer Center Stockholm and Gotland   (Sweden)

^bl Regional Cancer Center Uppsala Orebro   (Sweden)

^bm LUND UNIVERSITY HOSPITAL   (Sweden)

^bn KAROLINSKA INSTITUTE   (Sweden)

^bo Cancer Registry of Basel   (Switzerland)

^bp GENEVA CANCER REGISTRY   (Switzerland)

^bq St Gallen Cancer Registry   (Switzerland)

^br Ticino Cancer Registry   (Switzerland)

^bs Valais Cancer Registry   (Switzerland)

^bt National Institute for Cancer Epidemiology and Registration   (Switzerland)

^bu Eindhoven Cancer Registry   (Netherlands)

^bv Eastern Cancer Registration and Information Centre   (United Kingdom)

^bw Northern and Yorkshire Cancer Registry   (United Kingdom)

^bx Eastern Cancer Registration and Information Centre ^*  (United Kingdom)

^by Trent Cancer Registry   (United Kingdom)

^bz W Midlands Cancer Intelligence Unit   (United Kingdom)

^ca UNIVERSITY COLLEGE LONDON   (United Kingdom)

^cb Northern Ireland Cancer Registry   (United Kingdom)

^cc Scottish Cancer Registry   (United Kingdom)

^cd UNIVERSITY OF EDINBURGH   (United Kingdom)

^ce Welsh Cancer Intelligence Surveillance Unit   (United Kingdom)

more..

Author keywords

Acute myeloid leukaemia; Cancer registry; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Incidence; Myelodysplastic syndrome; Myeloid malignancies; Prevalence; Survival

Indexed keywords

EID: 84868215441     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.05.024     Document Type: Article

References (39)

1. E.S. Jaffe, N.L. Harris, H. Stein, and J.W. Vardiman World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001 IARC Press Lyon, France
2. S.H. Swerdlow, E. Campo, and N.L. Harris WHO classification of tumours of haematopoietic and lymphoid tissues 2008 IARC Press Lyon, France
3. C. Percy, K. Shanmugaratnam, and S. Whelan International Classification of Diseases for Oncology (ICD-O). 3rd ed 2000 WHO Geneva, Switzerland
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010: http://globocan.iarc.fr [Accessed on August 2011].
5. M. Sant, C. Allemani, and C. Tereanu Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project Blood 116 2010 3724 3734
6. G. Gatta, J.M. van der Zwan, and P.G. Casali Rare cancers are not so rare: the rare cancer burden in Europe Eur J Cancer 47 2011 2493 2511
7. Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and conversion programs for Cancer Registries. International Agency for Research on Cancer, Technical Report No. 42: Lyon (France); 2005: http://www.iacr.com.fr/TR42.htm [Accessed on August 2011].
8. R. De Angelis, S. Francisci, and P. Baili The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis Eur J Cancer 45 2009 909 930
9. R. Capocaccia, M. Colonna, and I. Corazziari Measuring cancer prevalence in Europe: the EUROPREVAL Project Ann Oncol 13 2002 831 839
10. R. Capocaccia, and R. De Angelis Estimating the completeness of prevalence based on cancer registry data Stat Med 16 1997 425 440
11. H. Brenner, and O. Gefeller An alternative approach to monitoring cancer patient survival Cancer 78 1996 2004 2010
12. Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Available from: http://seer.cancer.gov/csr/1975-2007/ [Accessed on August 2011].
13. M. Merhi, H. Raynal, and E. Cahuzac Occupational exposure to pesticides and risk of hematopoietic cancers: meta-analysis of case-control studies Cancer Causes Control 18 2007 1209 1226
14. A. Ahlbom, N. Day, and M. Feychting A pooled analysis of magnetic fields and childhood leukaemia British J Cancer 83 2000 692 698
15. J. Rudant, F. Menegaux, and G. Leverger Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE) Cancer Causes Control 19 2008 1277 1290
16. P. Latino-Martel, D.S. Chan, and N. Druesne-Pecollo Maternal alcohol consumption during pregnancy and risk of childhood leukemia: systematic review and meta-analysis Cancer Epidemiol Biomarkers Prev 19 2010 1238 1260
17. H. Hasle Pattern of malignant disorders in individuals with Down's syndrome Lancet Oncol 2 2001 429 436
18. S.M. Davies Therapy-related leukemia associated with alkylating agents Med Pediatr Oncol 36 2001 536 540
19. G. Gorini, E. Stagnaro, and V. Fontana Alcohol consumption and risk of leukemia: a multi center case-control study Leuk Res 31 2007 379 386
20. M.B. Cook, S.M. Dawsey, and N.D. Freedman Sex disparities in cancer incidence by period and age Cancer Epidemiol Biomarkers Prev 18 2009 1174 1182
21. J.L. Hornick, E.S. Jaffe, and C.D. Fletcher Extranodal histiocytic sarcoma: clinicopathological analysis of 14 cases of a rare epithelioid malignancy Am J Surg Pathol 28 2004 1133 1144
22. C.C. Kumar Genetic abnormalities and challenges in the treatment of acute myeloid leukemia Genes Cancer 2 2011 95 107
23. P.M. Carli, J.W. Coebergh, and A. Verdecchia Variation in survival of adult patients with haematological malignancies in Europe since 1978 Eur J Cancer 34 1998 2253 2263
24. M. Sant, T. Aareleid, and F. Berrino EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary Ann Oncol 14 2003 v61 118
25. M. Sant, C. Allemani, M. Santaquilani, A. Knijn, and F. Marchesi EUROCARE Working Group. EUROCARE-4: Survival of cancer patients diagnosed in 1995-1999. Results and commentary Eur J Cancer 45 2009 931 991
26. S. Castaigne, C. Chomienne, and M.T. Daniel All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results Blood 76 1990 1704 1709
27. D. Grimwade, H. Walker, and F. Oliver The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 1998 2322 2333
28. M.K. Jensen, P. De Nully Brown, O.J. Nielsen, and H.C. Hasselbalch Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area Eur J Haematol 65 2000 132 139
29. F. Passamonti, E. Rumi, and E. Pungolino Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 117 2004 755 761
30. C.S. Chim, Y.L. Kwong, and A.K. Lie Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia Arch Intern Med 165 2005 2651 2658
31. S. Corm, L. Roche, and J.B. Micol Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study Blood 118 2011 4331 4337
32. K.J. Phekoo, M.A. Richards, H. Moller, and S.A. Schey The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast England Haematologica 91 2006 1400 1404
33. X. Ma, M. Does, A. Raza, and S.T. Mayne Myelodysplastic syndromes: incidence and survival in the United States Cancer 109 2007 1536 1542
34. M. Maynadié, F. Girodon, and I. Manivet-Janoray Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France) Haematologica 96 2011 55 61
35. A. List, G. Dewald, and J. Bennett Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 2006 1456 1465
36. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
37. H. Kantarjian, J.P. Issa, and C.S. Rosenfeld Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
38. A. Quaglia, A. Tavilla, and L. Shack The cancer survival gap between elderly and middle-aged patients in Europe is widening Eur J Cancer 45 2009 1006 1016
39. R. De Angelis, C. Tereanu, and R. Capocaccia Prevalence of haematological malignancies in Europe, XXXV 12-14/05/2010 Annual conference of the Group of Latin Language Registries Toledo, Spain [oral communication]